PRACTICAL GUIDE | 2026

Get the class and grouping right before you build the dossier.

By Julio G. Martinez-Clark

CEO, bioaccess®

Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.

The short version

Risk classification is not a label you carry from the United States or Europe into Latin America. It is a country-specific regulatory decision that determines the registration route, grouping architecture, supporting evidence, fees, timing, and even which products can share one filing. Make that decision before translation and dossier assembly—not after an agency asks you to split the application.

Classification derails filings before the dossier does

When a medical-device registration stalls in Latin America, the instinct is to blame the dossier: a missing certificate, a bad translation, or an incomplete technical file. In practice, the more expensive mistake often happens earlier. The product was classified or grouped incorrectly before the dossier was built.

bioaccess® recently developed a Colombia-and-Peru registration strategy for a US electrosurgery manufacturer's full device line. The portfolio included generators, monopolar and bipolar instruments, reusable and single-use variants, neutral plates, cables, footswitches, and a factory kit. The hard question was not whether the documents existed. It was which products could legally share a registration—and why.

That distinction matters. A classification error can change the application type, evidence requirements, grouping logic, government fees, review clock, and number of registrations. If the error is found after filing, the sponsor may face an agency requirement, a forced split, or an entirely new submission.

Rule No. 1

Do not assume a US Food and Drug Administration product code or a European Union Medical Device Regulation class maps one-to-one onto a Latin American class. Each authority applies its own rules, definitions, intended-use analysis, and grouping criteria.

The country map: similar class numbers, different consequences

Use this as an orientation map, not as a substitute for a device-specific classification memo. The intended purpose, duration of use, invasiveness, active function, anatomy, and combination with other products can change the outcome.

Market	Risk classes	Core basis	What changes
Colombia — INVIMA	I, IIa, IIb, III	Decreto 4725/2005, as amended	I and IIa: automatic registration. IIb and III: full technical evaluation.
Peru — DIGEMID	I, II, III, IV	D.S. 016-2011-SA, as amended; Ley 29459	Low, moderate, high and critical risk. Approved family composition governs future additions.
Brazil — ANVISA	I, II, III, IV	RDC 751/2022	I and II: notificação. III and IV: registro.
Mexico — COFEPRIS	I, II, III	RIS, Art. 83; LGS, Art. 262	Check the low-risk no-registration list and available equivalence routes.
Argentina — ANMAT	I, II, III, IV	Disposición 2318/02 (TO 2004), as amended	Confirm the procedural dispositions in force at filing.
Chile — ISP	I, II, III, IV	Decreto Supremo 825/1998	Historically, mandatory registration has applied only to a listed subset. Confirm transition status.

Colombia: classification changes the procedure, not just the label

Decreto 4725 de 2005, as amended, establishes Classes I, IIa, IIb, and III in Article 5. Article 7 contains the 18 classification rules. Article 6 sets the implementing principles: intended purpose governs; products used in combination are classified separately; accessories are classified separately from the parent device; software that drives a device takes that device's class; and when several rules apply, the strictest rule governs.

The commercial consequence is immediate. Class I and IIa registrations proceed under Colombia's automatic-registration regime. Class IIb and III products receive a full technical evaluation. If the class is wrong, the sponsor has selected the wrong procedure—not merely the wrong box on a form.

Grouping requires equal care. Article 28 permits several devices to share a sanitary registration when they have the same risk classification, use, and generic denomination, and it addresses systems and kits used together. Under INVIMA's current grouping circulars—including Circular 5000-0001-22 and Circular 500-3052-16, subject to confirmation that they remain in force—exclusive parts, accessories, consumables, and spare parts may sometimes be covered by the parent equipment's registration. Factory kits must be assessed under the rules for kits and systems, with the highest-risk component governing classification.

Peru: the approved family defines what you can add later

Peru uses four classes under D.S. 016-2011-SA, as amended and issued under Ley 29459: Class I (low risk), Class II (moderate risk), Class III (high risk), and Class IV (critical risk).

Do not treat family composition as flexible after approval. The approved registration defines the family's scope. Adding products that fall outside that scope generally requires a new registration or a formal modification that DIGEMID may reject. The practical rule is simple: decide the family architecture before filing, and document why every model belongs.

Brazil: the current rule is RDC 751/2022

Brazil retains Classes I through IV under ANVISA RDC 751/2022, in force since March 2023. Classes I and II proceed through notificação; Classes III and IV require registro. RDC 185/2001 is revoked and should not be used as the operative legal basis. A classification error therefore changes the regulatory pathway.

Mexico: check the low-risk list before building a registration

Mexico uses Classes I, II, and III under Article 83 of the Reglamento de Insumos para la Salud; the medical-device definition appears in Article 262 of the Ley General de Salud. COFEPRIS also publishes an Acuerdo listing certain low-risk products that do not require sanitary registration. Missing that list can waste a full registration effort. Mexico also provides an equivalence route for qualifying devices with United States Food and Drug Administration or Health Canada approval; confirm eligibility for the exact product and current procedure.

Argentina and Chile: confirm the procedural regime in force

Argentina uses Classes I through IV under ANMAT Disposición 2318/02 (texto ordenado 2004), as amended. Confirm the procedural dispositions and submission route that are current when the filing starts.

Chile recognizes Classes I through IV under Decreto Supremo 825/1998, but historically mandatory Instituto de Salud Pública registration has applied only to a listed subset of medical devices. Do not describe Chile as a comprehensive mandatory-registration market without checking the current list. Chile is moving toward a broader medical-device law, so sponsors must confirm the transition status immediately before acting.

Scope carve-outs

This guide addresses general medical devices. In Colombia, in vitro diagnostic devices are governed separately by Decreto 3770 de 2004; Brazil also regulates IVDs under a separate RDC. Software as a medical device follows specialized rules and should receive its own classification analysis.

Five mistakes that create preventable delay

1. Treating FDA or EU classification as portable

A 510(k) letter, FDA product code, or EU Medical Device Regulation certificate is evidence. It is not a Latin American classification decision. Start with the intended purpose and the local rules in each country. Then use the foreign authorization to support—not replace—the local analysis.

The same warning applies to grouping. A set of models organized as one European technical-file "family" is not automatically one INVIMA family, one DIGEMID family, or one ANVISA notification. The legal tests are different.

2. Mixing risk classes inside an ordinary family

In the electrosurgery project, the manufacturer's first instinct was to group Class I neutral plates with Class IIb active electrodes in one monopolar family. That may look logical from a catalog perspective. It is not an ordinary family under Colombia's Article 28, which requires the same risk classification for ordinary grouping.

Filing Class I and IIb products as one ordinary family creates a predictable risk: an INVIMA request or a forced split. A defensible alternative may be to place exclusive accessories and consumables under the generator's registration, using the equipment-with-exclusive-accessories route in INVIMA's current grouping rules. When accepted, those accessories can be imported and marketed under the equipment's registration number. The factual record must show that the accessories were designed and approved for use with that equipment.

3. Hiding a multi-function kit inside a device family

A factory kit can combine products that do not share one function or class. In the real project, a blepharoplasty kit included monopolar and bipolar instruments, neutral plates, and cables. That commercial reference could not simply ride inside the monopolar family.

If the manufacturer wants to market the kit as a named, factory-established reference, assess it as a kit or system under Colombia's Article 28 and the applicable INVIMA grouping circulars. A separate registration may be required. The highest-risk component governs classification—a principle also reflected in the approaches used in Brazil and Argentina. Do not assume that bundling products in one box makes them one device.

4. Splitting variants automatically—or grouping them without evidence

In Colombia, sterile versus non-sterile, or single-use versus reusable, variants of the same device do not automatically require separate registrations when intended purpose, generic denomination, and risk classification remain compatible. The distinction still needs technical support through labeling, sterilization or reprocessing validation, shelf life, and the instructions for use.

Do not export that conclusion to every market. In other countries, these variants can affect grouping, evidence requirements, and, under some rule sets, classification itself. Run the local analysis.

5. Letting the documents contradict the strategy

A sound classification can still fail if the source documents disagree. Before filing, reconcile the Certificate to Foreign Government or Certificate of Free Sale, CE certificate, instructions for use, labels, technical files, and declarations of conformity. The names, models, intended uses, indications, sterility status, reusability, and claimed class must match the filing architecture.

Legalization, apostille, and validity-period problems for CFS/CFG and ISO 13485 certificates generate agency questions just as often as content inconsistencies. Check both substance and formal validity.

In the electrosurgery project, a reissued CE certificate added devices and changed the filing scope. But a model newer than the current CFG could not enter the submission merely because it appeared on the CE certificate. Those stock-keeping units became fileable only when the supporting market-authorization certificate was reissued to include them. One updated document does not cure a mismatch across the set.

Before you file: a classification and consistency check

Complete this review before translation, legalization, pricing, or submission. If any answer is uncertain, stop and resolve it before the dossier hardens around the wrong strategy.

• Freeze the intended purpose. Use one approved statement across the IFU, labels, certificates, technical file, and application.
• Classify country by country. Document the local rule, the facts that trigger it, and why stricter competing rules do or do not apply.
• Classify accessories separately. Then determine whether exclusive accessories qualify to sit under the equipment registration.
• Build a model-level matrix. List every catalog number, generic name, intended use, class, sterility, reusability, and proposed registration.
• Test every family. Confirm the models meet the local tests for class, use, generic denomination, design, and presentation.
• Test every kit. List each component and class; identify the highest-risk component; decide whether the named kit requires a separate registration.
• Reconcile every source document. Match product names, models, indications, class, sterility, and reusability across the CFG/CFS, CE certificate, IFUs, labels, technical files, and declarations.
• Check formal validity. Confirm issuer, validity period, legalization or apostille, and required translations for the CFS/CFG and ISO 13485 certificate.
• Verify the current procedure. Confirm that the law, agency circulars, low-risk lists, equivalence routes, and transition rules are still in force on filing day.
• Write the rationale. Keep a short classification-and-grouping memorandum in the submission file so the strategy can survive agency scrutiny and later portfolio additions.

The operating principle

Classification first. Grouping second. Document reconciliation third. Translation and filing come after all three are stable. Reversing that order turns a regulatory judgment into expensive rework.

Build the registration architecture before the agency does it for you

bioaccess® helps medical-device companies classify, group, and register portfolios across Latin America. Our Medical Device Registration & Market Access team supports ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, and DIGEMID strategies—from the first model matrix and document-gap review through local representation, submission, and post-market requirements.

If your portfolio includes multiple models, accessories, kits, sterile and reusable variants, or certificates that do not line up perfectly, resolve the architecture before filing. A short strategy review now is cheaper than a forced split later.

Talk with bioaccess® about your Latin America registration strategy

Regulatory references

• Colombia: Decreto 4725 de 2005, as amended; Decreto 3770 de 2004 for in vitro diagnostics; applicable INVIMA grouping circulars, including 5000-0001-22 and 500-3052-16, subject to confirmation that they remain in force.
• Peru: Ley 29459; Decreto Supremo 016-2011-SA, as amended.
• Brazil: ANVISA RDC 751/2022 for general medical devices; separate regulation applies to in vitro diagnostics.
• Mexico: Ley General de Salud, Article 262; Reglamento de Insumos para la Salud, Article 83; current COFEPRIS low-risk Acuerdo and equivalence procedures.
• Argentina: ANMAT Disposición 2318/02 (texto ordenado 2004), as amended, together with current procedural dispositions.
• Chile: Decreto Supremo 825/1998; current Instituto de Salud Pública mandatory-registration list and medical-device-law transition materials.

Last verified: September 2026

This guide is general information only and does not constitute legal or regulatory advice. Agency rules, circulars, lists, and procedures change frequently; confirm your strategy with qualified regulatory counsel before relying on it. Mike provides decision-support and is not a licensed attorney.